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Mesenchymal stem cells (MSCs) isolated from spinal ligaments with ectopic ossiﬁcation have a pro-
pensity toward the osteogenic lineage. To explore epigenetic control of the osteogenic features of MSCs,
we treated MSCs obtained from the spinal ligaments of ossiﬁcation of yellow ligament (OYL) patients and
non-OYL patients with the DNA methyltransferase inhibitor, 5-aza-20-deoxycytidine (5AdC). We
compared the non-OYL groups (untreated and treated with 5AdC) with the OYL groups (untreated and
treated with 5AdC) by genome-wide microarray analysis. Next, we used methylated DNA immunopre-
cipitation combined with quantitative real-time PCR to assess gene methylation. Ninety-eight genes
showed expression signiﬁcantly increased by 5AdC treatment in MSCs from non-OYL patients but not
from OYL patients. In contrast, only two genes, GDNF andWNT5A, showed signiﬁcantly higher expression
in OYL MSCs compared with non-OYL MSCs without 5AdC treatment. Both genes were hypermethylated
in non-OYL MSCs but not in OYL MSCs. Small interfering RNA targeted to each gene decreased expression
of the target gene and also several osteogenic genes. Both small interfering RNAs also suppressed the
activity of alkaline phosphatase, a typical marker of osteogenesis. These results suggest that the osteo-
genic features of MSCs from OYL patients are promoted by unmethylated WNT5A and GDNF genes.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ossiﬁcations of the posterior longitudinal ligament (OPLL) and/
or yellow ligaments (OYL) are characterized by progressive ectopic
bone formation in the spinal ligaments. In these patients, ectopic
ossiﬁcation sometimes occurs in other spinal ligaments. Conse-
quently, OPLL and OYL patients have been regarded as a manifes-
tation of diffuse idiopathic skeletal hyperostosis (DISH) (1,2). Based
on genetic factors, these current ﬁndings may indicate that OPLL
and OYL patients would have a tendency toward systemic ossiﬁ-
cation of numerous ligaments, similar to that observed in patients
with DISH. Although the etiology of ectopic ossiﬁcation of spinal
ligaments has been analyzed extensively and linked to various: þ81 172 39 5023.
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d/4.0/).epidemiological, genetic, metabolic, and mechanical factors (3), the
pathogenesis of the disease is still unknown. The ossiﬁcation of
spinal ligaments can lead to narrowing of the spinal canal, which
can eventually cause serious damage to the spinal cord, with pa-
tients suffering from various symptoms (4). Drug therapy is a
symptomatic treatment and cannot prevent progress of ectopic
bone formation. In severe cases, surgery is necessary to decompress
the spinal cord. However, surgery puts the patient at risk of com-
plications, such as injury to the spinal cord or nerve root and ce-
rebrospinal ﬂuid leakage (5). Furthermore, surgical treatment is not
always effective for patients with myelopathy, because long-term
compression results in irreversible degeneration of the spinal
cord (6). Therefore, it is necessary to understand the mechanisms
underlying the promotion of ossiﬁcation and to ﬁnd effective
therapies that prevent ectopic bone formation (3).
Mesenchymal stem cells (MSCs) can be isolated from various
human tissues and differentiated into osteoblastic, chondrogenic,
myogenic, and adipogenic lineages (7). MSCs have been regarded asnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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tigated for their potential role in treating human disease (8e10). We
previously identiﬁed the presence of MSCs in human spinal liga-
ments and, using immunohistochemistry, demonstrated enrich-
ment of MSCs in ossiﬁed areas of human spinal ligaments (11,12).
Furthermore, the osteogenic differentiation potential of MSCs from
patients with ossiﬁed spinal ligaments was increased; this pro-
pensity toward the osteogenic lineagemight be a causal factor in the
ossiﬁcation of these ligaments (13). However, the mechanism by
which MSCs obtain their osteogenicity remains unclear.
The behavior of MSCs, such as self-renewal, progression, and
differentiation is regulated through posttranscriptional, trans-
lational, posttranslational, and epigenetic processes (14). Epige-
netic regulation is based on heritable changes in the pattern of gene
expression that occurs without alterations in the primary nucleo-
tide sequence. Major epigenetic mechanisms include DNA
methylation and histone deacetylation, both of which are relevant
to gene expression. Recently, epigenetic regulation has emerged as
an important factor in cell differentiation, and epigenetic deregu-
lation has been associated with human diseases such as malig-
nancies. Given its associationwith various disease states, epigenetic
regulation has become an important focus of potential therapy (14).
Genetic factors are thought to be involved in ectopic ossiﬁcation
of spinal ligaments, because some patients have a positive family
history (15). However, multiple etiologic factors, including some
local factors, such as mechanical stress and cytokines, are also
thought to be important in ossiﬁcation of spinal ligaments (3). This
highlights the signiﬁcance of epigenetic changes in the character-
istics of MSCs.
We hypothesized that the propensity toward the osteogenic
lineage of MSCs from ossiﬁed spinal ligaments may be controlled by
epigenetic mechanisms. To examine the validity of the hypothesis,
we compared candidate genes that are suppressed by DNA methyl-
ation in MSCs between non-ossiﬁed spinal ligaments and ossiﬁed
spinal ligaments, using genome-wide cDNA microarray analysis.
2. Materials and methods
2.1. Samples
The study was approved by the Medical Ethics Committee of
Hirosaki University Graduate School of Medicine. All patients gave
written informed consent to participate. Ligamentum ﬂavum
samples were obtained from eight donor (four non-OYL and four
OYL) patients who underwent orthopedic surgery (patient infor-
mation is given in Table 1). The diagnosis of OYL or non-OYL (other
cervical disease not related to ectopic ossiﬁcation, e.g., cervical
spondylotic myelopathy) was conﬁrmed before surgery by spinal
surgeons using radiographs, computed tomography, and magnetic
resonance imaging of the cervical spine.
2.2. Cell isolation and culture
For the isolation of MSCs, the ligamentum ﬂavum was rinsed
with phosphate-buffered saline to remove blood, debris, andTable 1
Clinical diagnosis, gender, and age of patients who donated tissue samples.
Non-OYL OYL
Age/sex Diagnosis Age/sex Diagnosis
54/M Syringomyelia 55/M OYL
56/M Fracture 56/M OYL
76/F Thoracic myelopathy 75/M OYL
81/M Thoracic myelopathy 75/F OYL
M: male, F: female, OYL: ossiﬁcation of yellow ligament of the spine.surrounding tissue. Collected ligaments were minced into 0.5 mm3
pieces and washed twice with phosphate-buffered saline, then
digested using 3-mg/mL collagenase (Type 5; SigmaeAldrich, St.
Louis, MO) in a-modiﬁed Eagle's medium (a-MEM; Invitrogen,
Carlsbad, CA) at 37 C for 3 h. Digested tissue was ﬁltered through a
70-mm nylon ﬁlter (BD Biosciences, San Jose, CA) to remove debris.
Nucleated cells were resuspended after centrifugation, and then
plated in non-coated plastic dishes (Nalge Nunc International,
Rochester, NY) at a density of 5  105 cells/90-mm dish. Cells were
maintained in complete culture medium (a-MEM þ 10% fetal
bovine serum (JRH Bioscience, Lenexa, KS), 100-U/ml penicillin G
sodium and streptomycin sulfate (Invitrogen). Culture dishes were
incubated in a humidiﬁed atmosphere of 95% air and 5% CO2 at
37 C for 14 days as passage 0. Characterization of these cells was
presented in our previous study (11). Cells identiﬁed as MSCs by
ﬂow cytometry, as described previously (13), were used.
2.3. Demethylation of genomic DNA
Genomic DNA was demethylated by treatment with the DNA
methyltransferase inhibitor, 5-aza-20-deoxycytidine (5AdC) (Sigma,
Tokyo, Japan) (16). For treatment with 5AdC, 2  105 cells/10-cm
dish were seeded on day 0, and exposed to freshly prepared 30-
mM 5AdC for 24 h on days 1 and 3. This dose suppressed cellular
growth rates to approximately 70% of the growth rate of non-
treated cells (data not shown). On day 5, total RNA was extracted
fromMSCs using RNeasy Mini kits (Qiagen, Valencia, CA) according
to the manufacturer's instructions for mammalian cells, including
on-column DNA digestion using an RNase-free DNase set (Qiagen)
to avoid genomic DNA contamination. Genomic DNAwas extracted
from MSCs using a QIAamp DNA mini kit (Qiagen) according to the
manufacturer's instructions for mammalian cells.
2.4. Gene expression analysis (microarray)
The concentration of total RNA extracted from MSCs treated
with or without 5AdC was determined using a NanoDrop Spec-
trophotometer (NanoDrop Technologies, Wilmington, NC) and the
quality was assessed on an Agilent 2100 Bioanalyzer using an
Agilent RNA 6000 Nano Kit (Agilent Technologies, Santa Clara, CA).
RNA integrity was calculated, and RNA was ampliﬁed and labeled
using an Amino Allyl MessageAmp II aRNA Ampliﬁcation Kit
(Ambion, Tokyo, Japan) according to the manufacturer's protocol,
startingwith 750 ng of total RNA. Ampliﬁed aRNA from the samples
was labeled with Cy5. Universal Human Reference RNA (Stratagene,
Santa Clara, CA) was labeled with Cy3 and used as reference RNA.
Dye incorporation efﬁciency was measured using a NanoDrop
Spectrophotometer. Labeled sample aRNA corresponding to 200-
pmol Cy5 and reference aRNA corresponding to 130-pmol Cy3
were hybridized to in-house spotted arrays. Additionally, 20-pmol
Cy5 sample aRNA and 20-pmol Cy3 reference aRNA were hybrid-
ized to Agilent SurePrint G3 Human GE K Microarrays (Agilent
Technologies). Fragmentation, hybridization, and washing for both
the spotted arrays and Agilent arrays were carried out using the
Agilent Gene Expression Hybridization Kit and Gene Expression
Wash Buffer Kit (Agilent Technologies) in a low ozone environment
according to the manufacturer's protocol. Subsequently, the arrays
were scanned using an Agilent G2565CA Microarray Scanner
(Agilent Technologies). Microarray data have been deposited into
the Gene Expression Omnibus.
2.5. Real-time PCR analysis
Real-time PCR was carried out with Power SYBR Green PCR
Master Mix on an ABI Prism® 7000 Sequence Detection System
Table 3
Sequences of PCR primers for CpG islands.
Gene Forward primer (50e30) Reverse primer (50e30)
G3PDH CAGAGCCTCGAGGAGAAGTTC GGAACGACTGAGATGGGGAA
WNT5A TGGAAAAACGGGGAAAAGAGAG CTTATTGCTGTGCGGTGAGC
GDNF GGCTCTTTCGTTCTCGGTATTTG GAGACAAACTGAGAAGCCGAG
G3PDH: glyceraldehyde-3-phosphate dehydrogenase, WNT5A: wingless-type
MMTV integration site family member 5A, GDNF: glial cell-derived neurotrophic
factor.
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gene, as listed in Tables 2 and 3, were designed using Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The conditions
for PCR were: 95 C for 1 min, and 50 cycles of 95 C for 15 s, 60 C
for 1 min. All samples were analyzed in parallel for glycerol 3-
phosphate dehydrogenase (G3PDH) expression as an internal
standard. Real-time PCR data were represented as Ct values, where
Ct is deﬁned as the cycle number at which the amount of ampliﬁed
product exceeds the threshold level. We used the comparative Ct
method to compare the RNA expression in samples to that of the
control in each experiment. The primers were constructed so that
the dynamic range of the targets and the G3PDH reference was
similar over a wide range of dilutions (1:1 to 1:10,000). Reactions
were performed in triplicate for each cell preparation. The results
were expressed as themean ± SEM (n¼ 4) and the graphs show the
relative expression levels compared with the control (non-OYL
MSCs), unless otherwise stated.2.6. Methylated DNA immunoprecipitation (MeDIP)
Gene methylation status was quantitatively assessed by MeDIP
combined with real-time PCR using a primer set for the transcrip-
tion regulatory site of the genes of interest (17). MeDIP was carried
out using a MethylAfﬁnity™ Methylated DNA Enrichment Kit ac-
cording the manufacturer's instructions (GeneCopoeia, Inc., Rock-
ville, MD). Brieﬂy, genomic DNA (1 mg) was fragmented by
sonication to 250e500-bp fragments and then mixed with GCM™
beads followed by overnight incubation at 4 C on a rotisserie
shaker. The tubes were then centrifuged at 1000 g for 1 min to
pellet the beads. The supernatants were transferred to new tubes
and used to determine the fraction of unmethylated DNA. The
proportion of DNA in which the promoter regions were unmethy-
lated was assessed by real-time PCR using primers for CpG islands
in the promoter regions (Table 3). G3PDH was used as an internal
standard, because its expression was not changed by 5AdC treat-
ment (data not shown).2.7. RNA interference
The expression of WNT5A and GDNF was speciﬁcally inhibited
using OriGene 27 siRNA Knockdown Duplexes (OriGene, Rockville,
MD) according to the manufacturer's protocol. Brieﬂy, MSCs were
transfected with 3 nM small interfering RNA (siRNA) for each gene
or universal scrambled negative control siRNA duplex (SR30004;
OriGene) using siTran 1.0 Transfection Reagent (OriGene). Cells at
90% conﬂuency were incubated in siRNAwith siTrans1.0 þ siRNA at
37 C in a 5% CO2 incubator for 24 h. The following siRNAs were
used: WNT5A (SR305106A) (50e30): GGAUGUAGAAUGAUUAA
AGGUUGGT, GDNF (SR301776B) (50e30): GGAGUGCACUUGUUUGG
AAGUUCTG.Table 2
Sequences of real-time PCR primers used for gene expression.
Gene Forward primer (50e30) Reverse primer (50e30)
G3PDH TGCACCACCAACTGCTAGC GGCATGGACTGTGGTCATGAG
WNT5A TCACAGGTTCTCAGCCCAAG AGGGCTCAGTGTGAAGAGGA
GDNF CCAGAGGAAAAGGTCGGAGA CATAGCCCAGACCCAAGTCA
RUNX2 GCCTTCAAGGTGGTAGCCC CGTTACCCGCCATGACAGTA
BMP2 AGATGAACACAGCTGGTCACAGA GGAAGGATGCCCTTTTCCA
ALP ACGAGCTGAACAGGAACAACGT CACCAGCAAGAAGAAGCCTTTG
G3PDH: glyceraldehyde-3-phosphate dehydrogenase, WNT5A: wingless-type
MMTV integration site family, member 5A, GDNF: glial cell-derived neurotrophic
factor, RUNX2: runt-related transcription factor 2, BMP2: bone morphogenetic
protein 2, ALP: alkaline phosphatase.2.8. Alkaline phosphatase (ALP) assay
MSCs from OYL patients were seeded into a 6-well plate and
grown for 2 days until 90% conﬂuent, then transfected with siRNA
for GDNF, WNT5A, or universal scrambled negative control siRNA
before further culture for 24 h. The proteins were collected from the
cells using a lysis buffer (600 ml) containing 0.05% Triton X-100.
After two freeze/thaw cycles, ALP activity in the lysates was
measured using a LabAssay™ ALP kit (Wako Pure Chemical In-
dustries, Osaka, Japan) and standardized to whole protein content
in the lysate according to the manufacturer's instructions. The
experiment was performed once with duplicate wells for each
sample (n ¼ 4). ALP activity was expressed as IU/mg of protein.2.9. Statistical analysis
Data from eight samples (untreated and treated with 5AdC) in
each group (non-OYL and OYL) were used for statistical analyses.
Calculations were performed with SPSS ver.12.0 J (SPSS, Inc., Chi-
cago, IL). A comparison was made of all non-OYL groups (untreated
and treated with 5AdC) to all OYL groups (untreated and treated
with 5AdC). All quantitative values are expressed as mean ± SEM.
Experimental data from themicroarray analysis between the 5AdC-
treated group and the non-treated group were compared using the
unequal variance unpaired t-test (Welch test) with Benjami-
nieHochberg correction for multiple comparison. Gene expression
levels of each mRNA were compared between the non-OYL group
and the OYL group. p < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Effect of 5AdC on gene expression in OYL and non-OYL samples
The strategy to identify genes responsible for the osteogenic
feature of MSCs from patients with ossiﬁcation of spinal ligaments
was as follows (see also Fig. 1). In our experimental conditions,
three groups of genes were observed. Group 1 comprises genes
whose expression was signiﬁcantly increased by 5AdC in non-OYL
samples. These genes are normally suppressed by hyper-
methylation. Group 2 comprises genes whose expression did not
change signiﬁcantly upon 5AdC treatment in OYL samples. These
genes were released from restriction by hypermethylation. Group 3
comprises genes whose expression in OYL samples was signiﬁ-
cantly higher than that in non-OYL samples under normal condi-
tions (without 5AdC treatment). Candidate genes will reside in the
intersection among Groups 1e3. In the non-OYL group, 1269 genes
were down-regulated and 818 up-regulated by 5AdC compared
with control (considering p < 0.05 as the cut-off). In the OYL group,
1182 genes were down-regulated and 472 up-regulated by 5AdC
treatment compared with control (considering p < 0.05 as the cut-
off). 5AdC induced a signiﬁcant increase in the expression of 98
genes in MSCs from non-OYL patients, but did not change gene
expression in MSCs from OYL patients (i.e., the intersection be-
tween Groups 1 and 2). Only two genes, glial cell-derived
Fig. 1. Strategy for the identiﬁcation of susceptibility genes for ectopic ossiﬁcation of
spinal ligaments that are regulated by DNA methylation. To identify genes responsible
for the osteogenic features of MSCs from patients with ossiﬁcation of spinal ligaments,
we focused on three groups. The candidate genes will reside in the intersection among
Groups 1e3.
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site family member 5A (WNT5A), showed signiﬁcantly higher
expression (>2, considering p < 0.05 as the cut-off) in OYL MSCs
compared with non-OYL MSCs in normal culture conditions
without 5AdC (i.e., the intersection among Groups 1e3).
3.2. Real-time reverse transcriptase PCR analysis
To conﬁrm the microarray ﬁndings, we measured the mRNA
expression levels of WNT5A and GDNF by quantitative real-time
reverse transcriptase PCR. We demonstrated signiﬁcantly higher
expression of these two genes inMSCs fromOYL samples compared
with those from non-OYL samples. This was consistent with the
microarray data (Fig. 2).
3.3. Methylated DNA immunoprecipitation (MeDIP)
To assess the DNA methylation status of the promoter region of
the two genes, we carried out MeDIP combined with quantitative
real-time PCR. In the non-OYL group, the amount of unmethylated
CpG island in the promoter region of WNT5A and GDNF DNA was
low, but it increased signiﬁcantly after 5AdC treatment. In contrast,Fig. 2. Conﬁrmation of expression level of (A) WNT5A and (B) GDNF by real-time RT-PCR. m
treatment, analyzed by real-time RT-PCR. Speciﬁc primer pairs for each gene are listed in Tthere was no signiﬁcant change in the amount of unmethylated
WNT5A or GDNF DNA in the OYL group (Fig. 3). This suggests that
the expression of these genes was inhibited by DNA methylation of
the promoter region in non-OYL MSCs but not in OYL MSCs under
normal culture conditions.
3.4. Effect of siRNA-mediated gene silencing of GDNF and WNT5A
on osteogenic gene expression in OYL MSCs
siRNAs targeting GDNF or WNT5A signiﬁcantly decreased the
expression of each target gene in MSCs from OYL patients (Fig. 4).
Furthermore, siRNA treatment resulted in signiﬁcant down-
regulation of osteogenic genes such as RUNX2, BMP2, and ALP.
Negative control siRNA did not affect the expression of these genes
(see Fig. 4).
3.5. Effect of siRNA-mediated gene silencing of GDNF and WNT5A
on enzymatic ALP activity
Next, we investigated the effect of siRNA silencing of GDNF and
WNT5A on the functional activity of ALP, a marker of osteogenesis.
ALP leads to mineralization of the tissue (18). Both siRNAs signiﬁ-
cantly decreased ALP activity in cell lysate prepared fromOYLMSCs
(Fig. 5).
4. Discussion
By both microarray and real-time RT-PCR, we showed that
WNT5A and GDNF showed signiﬁcantly higher expression in OYL
MSCs than in non-OYL MSCs under normal culture conditions
without 5AdC treatment. In non-OYL MSCs, both genes were
hypermethylated, while in OYL MSCs, these genes were unmethy-
lated. Knockdownwith siRNAs decreased not only the expression of
the target gene but also that of several other osteogenic genes.
Furthermore, siRNA treatment suppressed the enzymatic activity of
ALP, a marker of osteogenesis. These data suggest that the
expression ofWNT5A and GDNFwas restricted by DNAmethylation
of the promoter region in non-OYL MSCs, and this epigenetic
regulation of both genes led to a tendency for ossiﬁcation of the
spinal ligaments in OYL patients.
The WNT gene encodes a secreted signaling protein that has
been implicated in oncogenesis and in several developmental
processes, including regulation of cell fate and patterning during
embryogenesis (19). During skeletal development,WNT signaling is
implicated in proximaledistal outgrowth and dorsoventral limbRNA expression levels of WNT5A and GDNF in non-OYL and OYL MSCs without 5AdC
able 2. Gene expression levels were normalized to those of G3PDH. **p < 0.01 (n ¼ 4).
Fig. 3. Effect of 5AdC on the amount of unmethylated DNA in the promoter region of (A)WNT5A and (B) GDNF. Non-OYL and OYL MSCs were treated with or without 5AdC and their
genomic DNA extracted. Fragmented DNAs were mixed with beads coated with anti-methyl cytidine antibody (GCM™ beads) and the methylated DNA fraction was sedimented
with the beads by centrifugation. The supernatants were used to determine the amount of unmethylated DNA in theWNT5A and GDNF promoter region by real-time PCR. **p < 0.01;
***p < 0.001 (n ¼ 4).
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and progression (20). As previously reported, the WNT signaling
pathway has emerged as a key regulator, including of skeletal
patterning (21). WNT signaling may regulate the maintenance and
differentiation of stem cells (22) and its inappropriate activation is
associated with a high frequency of tumors in speciﬁc tissues
including the intestine, liver, skin, and mammary gland (23). WNT
signaling has also been shown to be important in regulating bone
formation in mammals (24). WNT5A regulates osteoblastogenesis
and adipogenesis through the up-regulation of WNT/b-catenin
signaling (25). Osteoblast-lineage cells fromWNT5A-deﬁcient mice
exhibited impaired osteoblast differentiation. On the basis of the
above ﬁndings, it is probable that epigenetic regulation of the WNT
signaling pathway, i.e., higher expression of these genes, leads to
the tendency for ossiﬁcation of the spinal ligaments in OYL patients.Fig. 4. Inhibition of gene expression by siRNAs targeting WNT5A and GDNF. MSCs from OY
harvested and used for real-time RT-PCR. 1: negative control siRNA, 2: siRNA targeting GDN
expressed as fold increase compared with control (MSCs without siRNA transfection). *p <GDNFwasﬁrstdiscovered inglial cells (26), and its expressionhas
been found in a variety of tissues (27). GDNF is the most potent
survival factor identiﬁed in motor neurons (28): heterozygous
GDNF-knockoutmice lack22%of their lumbarmotorneurons (29). In
contrast, GDNF is produced by osteoblasts as well as bone marrow
stromal cells (30). GDNF is able to inﬂuence the proliferation of
calvarial osteoblasts and may be involved in the regulation of oste-
oblast recruitment in bonegrowth and remodeling (31). On the basis
of the above ﬁndings, it is probable that the epigenetic regulation of
GDNFsignaling is related tothe tendency forossiﬁcationof thespinal
ligaments in OYL patients. Furthermore, GDNF/WNT11 signaling
plays an important role inmorphogenesis of thekidney (32). GDNF is
mislocalized inWNT5A-deﬁcientkidneys (33). Thus, theremaybean
as-yet-unknown crosstalk between GDNF andWNT5A in the repair
processes of spinal ligaments. This warrants further study.L patients (n ¼ 4) were transfected with siRNA and cultured for 24 h. Total RNA was
F, 3: siRNA targeting WNT5A. Gene expression levels were normalized to G3PDH and
0.05; **p < 0.01 (n ¼ 4).
Fig. 5. Alkaline phosphatase (ALP) activity in MSCs treated with siRNAs targeting WNT5A and GDNF. Cell lysates prepared from siRNA-transfected OYL MSCs were assayed for ALP
enzymatic activity. **p < 0.01 (n ¼ 4).
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revealed thatmany genes demonstrated altered expression inMSCs
from non-OYL or OYL patients treated with 5AdC. A proportion of
such changes may directly reﬂect demethylation of the target gene;
however the rest might be indirect effects resulting from in-
teractions among the genes. Therefore, further studies should
examine the effect of other genes on methylation status. Second,
we used an indirect method to measure DNA methylation statusd
the sensitivity of mRNA expression to 5AdC. It may be more valid to
assess this directly using microarray analysis of the methylation
status of promoter regions and CpG islands. Third, epigenetic
changes include not only DNA methylation but also histone modi-
ﬁcation (acetylation, methylation, phosphorylation, ubiquitination,
sumoylation); frequently, more than one mechanism is tightly
linked to the regulation of gene expression. Therefore, it is neces-
sary to examine the inﬂuence of histone modiﬁcation. Fourth, we
did not attempt direct inhibition of the ossiﬁcation of OYL MSCs,
because this requires multiple siRNA transfections over several
weeks, resulting in cytotoxicity. In future studies, we will contin-
uously inhibit the two genes using methods such as gene editing
with CRISPR/Cas9.
In summary, by genome-wide microarray analysis we revealed
that 5AdC induced a signiﬁcant increase in the expression of 98
genes in MSCs from non-OYL patients, which were not changed in
MSCs from OYL patients. Only two such genes, GDNF and WNT5A,
showed signiﬁcantly higher expression in OYL MSCs compared
with in non-OYL MSCs under normal culture conditions without
5AdC treatment. Then, using MeDIP combined with real-time PCR,
we quantitatively assessed the methylation status of these two
genes. Theywere hypermethylated in non-OYLMSCs but not in OYL
MSCs. These results suggest that the osteogenic features of MSCs
from OYL patients are promoted by unmethylated WNT5A and
GDNF genes.Conﬂict of interest
No conﬂicts of interest, ﬁnancial or otherwise, are declared by
Japanese Pharmacological Society.Acknowledgments
This project was funded by an AOSpine Japan research grant
(2013); a Grant-in-Aid from the Investigation Committee on Ossiﬁ-
cation of the Spinal Ligaments; the Public Health Bureau of the
JapaneseMinistry of Labour, Health, andWelfare; and byaGrant-in-
Aid from the Ministry of Education, Culture, Sports, Science, and
Technology of Japan (no. 24590310). We thank Drs. Kazumasa
Ueyama, Naoki Echigoya, Akio Sannohe, Takuya Numasawa, Toru
Yokoyama, Kazunari Takeuchi, Shuichi Aburakawa, Yoshihito
Yamasaki, Taisuke Nitobe, Kenji Kowatari and Takashi Tomita for
their contributions to sample collection. Japanese Pharmacological
Society acknowledge toDr. Taito Itabashi for his valuable comments.References
(1) Resnick D, Shaul SR, Robins JM. Diffuse idiopathic skeletal hyperostosis
(DISH): Forestier's disease with extraspinal manifestations. Radiology.
1975;115:513e524.
(2) Utsinger PD. Diffuse idiopathic skeletal hyperostosis. Clin Rheum Dis.
1985;11:325e351.
(3) Furukawa K-I. Pharmacological aspect of ectopic ossiﬁcation in spinal liga-
ment tissues. Pharmacol Ther. 2008;118:352e358.
(4) Matsunaga S, Kukita M, Hayashi K, Shinkura R, Koriyama C, Sakou T, et al.
Pathogenesis of myelopathy in patients with ossiﬁcation of the posterior
longitudinal ligament. J Neurosurg. 2002;96:168e172.
(5) Choi S, Lee SH, Lee JY, Choi WG, Choi WC, Choi G, et al. Factors affecting
prognosis of patients who underwent corpectomy and fusion for treatment of
cervical ossiﬁcation of the posterior longitudinal ligament: analysis of 47
patients. J Spinal Disord Tech. 2005;18:309e314.
(6) Koyanagi I, Iwasaki Y, Hida K, Imamura H, Abe H. Magnetic resonance imaging
ﬁndings in ossiﬁcation of the posterior longitudinal ligament of the cervical
spine. J Neurosurg. 1998;88:247e254.
(7) Luu HH, Song WX, Luo X, Manning D, Luo J, Deng ZL, et al. Distinct roles of
bone morphogenetic proteins in osteogenic differentiation of mesenchymal
stem cells. J Orthop Res. 2007;25:665e677.
(8) Min KJ, So KA, Ouh YT, Hong JH, Lee JK. The effects of DNA methylation and
epigenetic factors on the expression of CD133 in ovarian cancers. J Ovarian
Res. 2012;5:28.
(9) Yan H, Yu N, Tong J. Effects of 5-Aza-20-deoxycytidine on the methylation
state and function of the WWOX gene in the HO-8910 ovarian cancer cell line.
Oncol Lett. 2013;6:845e849.
(10) Wang Z, Li L, Su X, Gao Z, Srivastava G, Murray PG, et al. Epigenetic silencing of
the 3p22 tumor suppressor DLEC1 by promoter CpG methylation in non-
Hodgkin and Hodgkin lymphomas. J Transl Med. 2012;10:209.
N. Chiba et al. / Journal of Pharmacological Sciences 127 (2015) 467e473 473(11) Asari T, Furukawa K-I, Tanaka S, Kudo H, Mizukami H, Ono A, et al. Mesen-
chymal stem cell isolation and characterization from human spinal ligaments.
Biochem Biophys Res Commun. 2012;417:1193e1199.
(12) Chin S, Furukawa K-I, Ono A, Asari T, Harada Y, Wada K, et al. Immunohis-
tochemical localization of mesenchymal stem cells in ossiﬁed human spinal
ligaments. Biochem Biophys Res Commun. 2013;436:698e704.
(13) Harada Y, Furukawa K-I, Asari T, Chin S, Ono A, Tanaka T, et al. Osteogenic
lineage commitment of mesenchymal stem cells from patients with ossiﬁ-
cation of the posterior longitudinal ligament. Biochem Biophys Res Commun.
2014;443:1014e1020.
(14) Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and
prospects for epigenetic therapy. Nature. 2004;429:457e463.
(15) NakajimaM, Takahashi A, Tsuji T, Karasugi T, Baba H, Uchida K, et al. A genome-
wide association study identiﬁes susceptibility loci for ossiﬁcation of the pos-
terior longitudinal ligament of the spine. Nat Genet. 2014;46:1012e1017.
(16) Yamashita S, Takahashi S, McDonell N, Watanabe N, Niwa T, Hosoya K, et al.
Methylation silencing of transforming growth factor-beta receptor type II in
rat prostate cancers. Cancer Res. 2008;68:2112e2121.
(17) Mohn F, Weber M, Schubeler D, Roloff TC. Methylated DNA immuno precip-
itation (MeDIP). Methods Mol Biol. 2009;507:55e64.
(18) Narisawa S, Yadav MC, Millan JL. In vivo overexpression of tissue-nonspeciﬁc
alkaline phosphatase increases skeletal mineralization and affects the phos-
phorylation status of osteopontin. J Bone Miner Res. 2013;28:1587e1598.
(19) Rijsewijk F, Schuermann M, Wagenaar E, Parren P, Weigel D, Nusse R. The
Drosophila homology of the mouse mammary oncogene int-1 is identical to
the segment polarity gene wingless. Cell. 1987;50:649e657.
(20) HuH,HiltonMJ, TuX, YuK, Ornitz DM, Long F. Sequential roles of Hedgehog and
Wnt signaling in osteoblast development. Development. 2005;132:49e60.
(21) Cabrera CV, Alonso MC, Johnston P, Phillips RG, Lawrence PA. Phenocopies
induced with antisense RNA identify the wingless gene. Cell. 1987;50:
659e663.(22) Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer.
Nature. 2001;411:349e354.
(23) Noort van M, Clevers H. TCF transcription factors, mediators of Wnt-signaling
in development and cancer. Dev Biol. 2002;244:1e8.
(24) Long F. Building strong bones: molecular regulation of the osteoblast lineage.
Nat Rev Mol Cell Biol. 2011;13:27e38.
(25) Okamoto M, Udagawa N, Uehara S, Maeda K, Yamashita T, Nakamichi Y, et al.
Noncanonical Wnt5a enhances Wnt/b-catenin signaling during osteoblasto-
genesis. Sci Rep. 2014;4:4493.
(26) Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived
neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260:
1130e1132.
(27) Suter-Crazzolara C, Unsicker K. GDNF is expressed in two forms in many
tissues outside the CNS. Neuroreport. 1994;20:2486e2488.
(28) Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M,
et al. GDNF: a potent survival factor for motoneurons present in peripheral
nerve and muscle. Science. 1994;266:1062e1064.
(29) Moore MW, Klein RD, Fari~nas I, Sauer H, Armanini M, Phillips H, et al. Renal
and neuronal abnormalities in mice lacking GDNF. Nature. 1996;382:76e79.
(30) Jiang J, Lv Z, Gu Y, Li J, Xu L, Xu W, et al. Adult rat mesenchymal stem cells
differentiate into neuronal-like phenotype and express a variety of neuro-
regulatory molecules in vitro. Neurosci Res. 2010;66:344e346.
(31) Gale Z, Cooper PR, Scheven BA. Glial cell line-derived neurotrophic factor
inﬂuences proliferation of osteoblastic cells. Cytokine. 2012;57:276e281.
(32) Majumdar A, Vainio S, Kispert A, McMahon J, McMahon AP. Wnt11 and Ret/
Gdnf pathways cooperate in regulating ureteric branching during meta-
nephric kidney development. Development. 2003;130:3175e3185.
(33) Yun K, Ajima R, Sharma N, Costantini F, Mackem S, Lewandoski M, et al. Non-
canonical Wnt5a/Ror2 signaling regulates kidney morphogenesis by con-
trolling intermediate mesoderm extension. Hum Mol Genet. 2014;23:
6807e6814.
